{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:46:13Z","timestamp":1794501973523,"version":"4.9.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.amjcard.2025.08.046","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:07:51Z","timestamp":1756825671000},"page":"49-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A Phase 1b Randomized Clinical Trial of AZD5462 and Dapagliflozin in Patients with Heart Failure and Moderate Renal Impairment"],"prefix":"10.1016","volume":"258","author":[{"given":"Macarena Paz","family":"Quintana-Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Greasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Sadaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Svedlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya Birgitte","family":"Rosenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2025.08.046_bib0001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7812\/TPP\/18.273","article-title":"Prognostic impact of chronic kidney disease in patients with heart failure","volume":"23","author":"Hakopian","year":"2019","journal-title":"Perm J"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0003","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-021-22331-9","article-title":"Single-cell RNA sequencing reveals the mesangial identity and species diversity of glomerular cell transcriptomes","volume":"12","author":"He","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0004","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jsgi.2004.05.002","article-title":"Mechanisms of renal vasodilation and hyperfiltration during pregnancy","volume":"11","author":"Conrad","year":"2004","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0005","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1152\/ajpregu.00156.2011","article-title":"Maternal vasodilation in pregnancy: the emerging role of relaxin","volume":"301","author":"Conrad","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/ndt\/gfae112","article-title":"Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial","volume":"40","author":"Tham","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0007","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1161\/CIRCULATIONAHA.121.053659","article-title":"Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0008","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0009","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Committees D-CT, Investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12933-022-01574-w","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis","volume":"21","author":"Li","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0011","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/ndt\/gfad112","article-title":"SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA","volume":"38","author":"Mark","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0012","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis","volume":"36","author":"Cardoso","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0014","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabet Endocrinol"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2025.08.046_bib0016","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925005107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925005107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:52:34Z","timestamp":1772848354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925005107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"alternative-id":["S0002914925005107"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.08.046","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1b Randomized Clinical Trial of AZD5462 and Dapagliflozin in Patients with Heart Failure and Moderate Renal Impairment","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}